Use of effective part of traditional Chinese medicine in HIV latency-resistant treatment
A technology of effective parts and latent infection, applied in the field of medicine, can solve the problems of high toxicity and side effects, unsatisfactory, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0071] Preparation of effective anti-HIV fraction of Atractylodes macrocephala
[0072] The traditional Chinese medicine Atractylodes Rhizoma Atractylodes Rhizoma Atractylodes Rhizoma Atractylodes Rhizoma Atractylodes Rhizoma Atractylodes Rhizoma Atractylodes Rhizoma Atractylodes Rhizome (1kg, chopped medicinal material) was reflux extracted with 95% ethanol (8L x 3), and the ethanol was recovered to obtain an ethanol extract (0.19kg).
[0073] The ethanol extract was dissolved in 200mL hot water, and after cooling, it was sequentially extracted with petroleum ether (200mL x 3) and dichloromethane (200mL x 3) to obtain a dichloromethane extract (21g).
[0074] The dichloromethane extract was subjected to silica gel column chromatography (1kg, column diameter: 10cm), eluted with petroleum ether: ethyl acetate (100:1) (10L) to remove the fat part, and then washed with petroleum ether: ethyl acetate (1: 1) (10L) was eluted to obtain the effective fraction (9.1g).
[0075] The ob...
Embodiment 2
[0082] Effects of effective fractions on HIV latency-induced activation
[0083] 1. Method
[0084] C11 cell is a latently infected cell model of HIV, which is obtained by infecting the human T lymphocyte cell line Jurkat with HIV-1 lentivirus carrying the EGFP reporter gene, through cell sorting and HIV integration detection, and has HIV integration but no expression EGFP T lymphocyte line. C11 cells are Jurkat stable strains that are infected by the HIV lentivirus carrying the reporter gene GFP and do not express at the same time, so they are used for screening and activating HIV-1 drugs for latent infection (see application number 200810038851.X, invention title "a screening for activating latent infection HIV-1 compound T lymphocytes and its preparation method" Chinese patent application), the preservation number is CCTCCNO.C200821.
[0085] In this example, 2×10 per hole 4 C11 cells were planted in a 96-well plate, and 100 μl of 1640 medium (Gibco) containing 10% FBS (...
Embodiment 3
[0090] Effects of Different Concentrations of Effective Fractions on HIV Latency Induction and Activation
[0091] Repeat Example 2, the only difference is that the effective fraction of Atractylodes Rhizome with a final concentration of 0.2 μg / mL, 0.5 μg / mL, 2 μg / mL, or 5 μg / mL is used to replace the effective fraction of Atractylodes Rhizome with a final concentration of 1 μg / mL.
[0092] The results showed that, at the above concentrations, the proportion of green fluorescent positive cells in HIV latently infected cells treated with different active parts of Atractylodes macrocephala was 10-80%, much higher than the background activation of less than 1% in the control. This shows that the effective part of the present invention has a significant intervention effect on HIV latently infected cells.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 